Several PHRI researchers presented at the 19th Cardiovascular Clinical Trialists (CVCT) Global Forum in Washington, DC Dec. 1 – 3, 2022 on topics ranging from the polypill to accelerating CV trials, from heart failure polypharmacy implementation to anti-thrombotic therapy.
Polypill and Fixed Dose Combination Strategies: How to Act upon the Accumulated Evidence, chaired by PHRI Executive Director Salim Yusuf, and PHRI Senior International Fellow Clara Chow, included: Yusuf on history of the polypill and its essential role in global CVD prevention; the evidence so far – a summary of trials of the polypill in primary prevention by PHRI Investigator Philip Joseph, and cost effectiveness of the polypill by PHRI Scientist André Lamy.
Dr. Philip Joseph @PHRIresearch discusses the growing evidence (HOPE-3, POLYIRAN, TIPS-3, SRMAs) supporting the #Polypill in primary cardiovascular disease prevention. #CVCT2022 pic.twitter.com/ml9e59XqvJ
— Dominique Vervoort (@DVervoort94) December 1, 2022
Accelerating CV Clinical Trials: Regulatory Digital and Investigator Solutions included “a la COVID” non-competitive model by PHRI Senior Scientist PJ Devereaux, and Yusuf on conducting randomized clinical trials in developing countries and in resource-challenged settings.
“80% of #CVD burden is in low- and middle-income countries, but it is largely ignored .. <10% of research is conducted there.”
“Avoid neo-colonialism!” pic.twitter.com/9Z6CS61fmC
— Dominique Vervoort (@DVervoort94) December 2, 2022
Thrombosis Trials: Solving the Equation of Maximizing the Net Benefit of Anti-Thrombotic Therapy included: Will XIa have different benefits on MIs and Stroke, and DVTs? by PHRI Senior Scientist Guillaume Pare; and Devereaux on myocardial infarction following non-cardiac surgery.